Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT® FDA Clinical Trial
September 12, 2018 08:00 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by...
Nemaura Medical Strengthens Manufacturing Team in Preparation for SugarBEAT® Commercial Launch.
August 28, 2018 08:00 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive glucose trending device for use by...
Nemaura Medical Inc. Reports First Quarter 2018 Financial Results
August 09, 2018 08:00 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive glucose trending device for use by persons with diabetes and...
Nemaura Initiates US FDA Studies, and Reports Positive Interim Data from Home-Use Portion of Study
July 31, 2018 08:00 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive glucose trending device for use by persons with diabetes and...